1	Improvement of Survival Outcomes of
2	Cholangiocarcinoma by Ultrasonography Surveillance:
3	<b>Multicenter Retrospective Cohorts</b>
4	
5	Nittaya Chamadol <sup>1, 11</sup> , Vallop Laopaiboon <sup>1, 11</sup> , Apiwat Jareanrat <sup>2, 11</sup> Vasin Thanasukarn <sup>2, 11</sup> ,
6	Tharatip Srisuk <sup>2, 11</sup> , Vor Luvira <sup>2, 11</sup> , Poowanai Sarkhampee <sup>3</sup> , Winai Ungpinitpong <sup>4</sup> , Phummarat
7	Khamvijite <sup>4</sup> , Yutthapong Chumnanua <sup>5</sup> , Nipath Nethuwakul <sup>5</sup> , Passakorn Sodarat <sup>5</sup> , Samrit
8	Thammarit <sup>6</sup> , Anchalee Techasen <sup>7,11</sup> , Jaruwan Thuanman <sup>8,11</sup> ,
9	Chaiwat Tawarungruang <sup>8,11</sup> , Bandit Thinkhamrop <sup>8,11</sup> , Prakasit Sa-Ngiamwibool <sup>9,11</sup> ,
10	Watcharin Loilome <sup>10,11</sup> , Piya Prajumwongs <sup>11</sup> , & Attapol Titapun <sup>2,11,*</sup>
11	
12	
 13	<sup>1</sup> Departments of Radiology, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand
14	<sup>2</sup> Departments of Surgery, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand
15	<sup>3</sup> Departments of Surgery, Sunpasittiprasong Hospital, Ubon Ratchathani Province, Thailand
16	<sup>4</sup> Departments of Surgery, Surin Hospital, Surin Province, Thailand
17	<sup>5</sup> Departments of Surgery, Roi Et Hospital, Roi Et Province, Thailand
18	<sup>6</sup> Departments of Surgery, Udon Thani Hospital, Udon Thani Province, Thailand
19	<sup>7</sup> Departments of Clinical Microbiology, Faculty of Associated Medical Sciences, Khon Kaen University, Khon
20	Kaen, Thailand
21	<sup>8</sup> Data Management and Statistical Analysis Center (DAMASAC), Faculty of Public Health, Khon Kaen
22	University, Khon Kean, Thailand
23	<sup>9</sup> Department of Pathology, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand
24	<sup>10</sup> Systems Biosciences and Computational Medicine, Faculty of Medicine, Khon Kaen University, Khon Kaen,
25	Thailand
26	<sup>1</sup> NOTED Inngjøepanni nepous Revouselar En stritutus Kolvouek aenifel u bygreetyre Kolvoun Ksionyld havilændsed to guide clinical practice.

2

#### 27 \* Corresponding author

28 E-mail: attati@kku.ac.th (AT)

29

## 30 Abstract

#### 31 Introduction

32 Most cholangiocarcinoma (CCA) patients present with late stage of disease because of the

difficulty to diagnosis at an early stage, resulting in poor survival of CCA patients. The

34 Cholangiocarcinoma Screening and Care Program showed that ultrasound screening was an

effective tool for detecting early stage CCA. This study aims to evaluate the survival outcome

36 of patients diagnosed by ultrasound screening (US) compared to walk-in symptomatic

37 patients.

#### 38 Methods

39 5-year survival rates (5-YSR) and median survival time (MST) of CCA were calculated using

40 Log-Rank test. Multivariate analyses were performed for significant factors from univariate

41 analyses.

#### 42 **Results**

43 A total of 711 histologically proven CCA cases were examined including ultrasound

screening and walk-in groups. The screening group having 5-YSR was 53.9%, and MST was

- 45 of 67.2 months, while walk-in group, the 5-YSR was 21.9% and MST was 15.6 months
- 46 (p < 0.001). In addition, multivariate analyses revealed that screening program was an
- 47 independent factor to predict a good outcome of CCA patients when compared with walk-in

48 group (p = 0.014).

#### 49 **Conclusion**

3

US is an effective tool for detecting early stage CCA leading to improve clinical outcome of
CCA patients. Practically, US should be considered as a first tool for screening CCA in risk
populations.

53

#### 54 Author Summary

55 Most cholangiocarcinoma (CCA) patients in Thailand have poor survival due to late-stage 56 detection and patients walk-in to hospital with any symptoms. This study purpose to evaluate 57 the survival outcome of CCA patients diagnosed by ultrasound screening (US). We found that 58 US provided early stage and improved survival of CCA patients.

# 59 Introduction

Cholangiocarcinoma (CCA) is a cancer of bile duct epithelium which the second most 60 common primary liver cancer worldwide after hepatocellular carcinoma (HCC). CCA has a 61 relatively rare incidence in most western countries and North America, however, it has been 62 reported as having high incidence rates in East and Southeast Asia, especially in Thailand. The 63 incidence of CCA in the northeast of Thailand has been recorded as the highest incidence rate 64 worldwide with an incidence of 87.7 per 100,000 in males, and 36.3 per 100,000 in females 65 66 [1]. The major risk factor of CCA in Thailand has been identified as infection by the liver fluke Opisthorchis viverrini (OV) which initiates the development of the normal bile duct to 67 68 transform into tumor known as cholangiocarcinogenesis [2-4].

69 CCA patients have poor survival and high mortality rate due to late diagnosis. 70 Diagnosis of CCA is rare at an early stage because most patients with any clinical symptoms 71 were diagnosed at the advance or locally advance stage. Surgical resection is potentially the 72 most curative treatment considered as a first choice for treatment in resectable patients in every 73 type of CCA [5, 6]. Surgical resection offers the best opportunity for long-term survival with 74 survival time approximately 17-20 months and 5-year survival rate 10-25% [7-12]. Although

4

surgical resection provides long-term overall survival, candidate surgical patients have been 75 reported to be only 20%, while 80% are diagnosed at unresectable stage CCA [13]. The 76 unresectable CCA patients suffer from several complications for instance, local tumor invasion 77 or distant metastasis, biliary obstruction, cholangitis, pain, and malnutrition [13]. These 78 complications reduced the quality of the patient's life, with subsequent poor survival of 79 unresectable CCA patients. Thus, a screening test for diagnosis of CCA at an early stage of 80 81 disease has diagnostic and clinical advantages for the early treatment of CCA which improves a patient's outcomes. 82

83 Trans-abdominal ultrasonography (US) is a non-invasive imaging tool to detect abnormality in the hepatobiliary system, including early stage CCA by detecting mass and/or 84 dilatation of bile ducts. US also offers several advantages, due to its accessibility, speed, ease 85 of performance, portability and low cost [14]. Therefore, US should be considered as the first-86 87 choice imaging modality for screening abnormalities associated with CCA in Thailand [15-19]. Ultrasound screening was systematically applied in the Cholangiocarcinoma Screening 88 and Care Program (CASCAP), to determine the utility of the application for early diagnosis of 89 CCA combined with prevention, treatment, and follow-up. This prospective study consisted of 90 two cohorts, the screening cohort included people at risk of CCA without any symptoms who 91 received active ultrasound screening, and the patient cohort included symptomatic walk-in 92 93 patients [20]. Results showed that US screening can diagnose early signs of biliary tract fibrosis 94 (periductal fibrosis) that is associated with CCA [15] as well as detecting premalignant CCA lesions and early stage CCA [21]. Subsequently, CCA patients who were diagnosed by US 95 screening had significantly higher proportion of early stage CCA compared to symptomatic 96 97 walk-in patients [17]. Early-stage detection in the screening group may provide better survival outcomes than the walk-in group of CCA, significant benefits for early treatment and reduction 98 of morbidity and mortality rates of CCA patients. 99

5

100 Therefore, this study aimed to evaluate the effectiveness of US screening by comparing
101 the survival outcome between the screening group and symptomatic walk-in patient group.
102

103

## 104 Methods

#### 105 Ethics statement and consent to participate

This study was conducted based on the principles of Good Clinical Practice, the Declaration of Helsinki, and national laws and regulations about clinical studies. All processes of this study were accepted and approved by the Khon Kaen University Ethics Committee for Human Research under the reference number HE551404. The data underwent complete anonymization before our access. Information could not identify individual participants. Clinical data and medical records of patients were retrieved through only hospital number (HN). Clinical data and medical records for this study were accessed in 30 June 2021.

113

## 114 **Overview of study design**

A total of 766 CCA patients were included in this study who underwent surgery and 115 CCA was confirmed by pathologists in 11 hospitals over the period of 1 October 2013 to 30 116 June 2021, namely: (1) Srinagarind Hospital, Khon Kaen University; (2) Sunpasittiprasong 117 Hospital; (3) Surin Hospital; (4) Udon Thani Hospital; (5) Roi Et Hospital; (6) Udonthani 118 Cancer Hospital; (7) Maharaj Nakorn Chiang Mai Hospital; (8) Buri Ram Hospital; (9) 119 Ubonratchathani Cancer Center; (10) Khon Kaen Hospital and (11) Maharat Nakhon 120 Ratchasima Hospital. Demographic and pathological data that were recorded by the 121 Cholangiocarcinoma Research Institute (CARI), Khon Kaen University were reviewed. 122 Patients in this study were separated into two groups: the screening group (n = 163) comprised 123

6

individuals diagnosed by US screening who had no clinical symptoms that could be related to 124 CCA and the walk-in group (n = 603) which comprised patients presenting with clinical 125 symptoms and confirmed CCA by CT/MRI. A total of 55 patients were excluded from the 126 study as they did not receive curative surgery due to the advanced CCA stage, unresectable or 127 had distant metastasis (5 cases in screening and 23 cases in walk in groups), and patients who 128 had survival time less than 30 days (4 cases in screening and 23 cases in walk in groups). 129 130 Therefore, a total of 711 cases were included in this study comprising the screening group of 154 cases and walk-in group of 557 cases (Fig 1). 131

132

#### 133 Fig 1. The schematic of the study.

#### **Diagnosis and treatment**

Patients in screening groups who underwent abdominal US examination and 135 confirmed by CT/MRI. US and CT/MRI images of both groups were reviewed by radiologist 136 (NC and VL). Intraoperative findings and operative procedure were reviewed. 137 Histopathological diagnosis and tumor morphology of both groups were reviewed by 138 pathologists (PS). Tumor staging was recorded according to AJCC 8<sup>th</sup> edition. Adjuvant 139 chemotherapy was provided to patients by attended oncologists or by a multidisciplinary 140 team conference at each treatment center. Patients were followed up with CT/MRI and tumor 141 markers every 3-6 months. If recurrence of disease occurred, a different chemotherapy 142 regimen was considered and applied for appropriate patients. 143 144

### 145 Data management and statistical analysis

146 The demographic characteristics of the patients were presented as the mean and standard

147 deviation for continuous variables and frequency counts with their percentages for categorical

variables. Both of these were presented for each comparison group and as a total for the

7

purpose of comparison and characterizing the patient cohort, respectively. The proportion of
early stage CCA was calculated by using the number of patients whose stage was 0, I, or II as
the numerator and the total number of patients as the denominator.

Survival analysis was calculated by Kaplan-Meier method. Survival time was defined as from the date of surgery to the date of the patient's death. Patients who survived after the end of study date ( $30^{th}$  December 2021) were defined as censor. Median survival times and survival rates are presented with 95%CI and the comparison between groups was analyzed by log rank test. Univariable and multivariable analyses were performed to identify prognostic factors using the Cox regression model. A *p*-value of less than 0.05 was considered significant. All analyses were performed using the IBM SPSS Statistics version 26.

159

## 160 **Results**

## 161 Patient's characteristics and overall survival of CCA patients

## 162 between screening and walk-in

The number and proportion of CCA patients who received curative surgery in 11 163 hospitals are as follows: (1) Srinagarind Hospital, Khon Kaen University, n = 493 (69.3%); 164 (2) Sunpasittiprasong Hospital, n = 62 (8.7%); (3) Surin Hospital, n = 48 (6.7%), (4) Udon 165 Thani Hospital, n = 44 (6.2%); (5) Roi Et Hospital, n = 41 (5.8%); (6) Udonthani Cancer 166 Hospital, n = 8 (1.1%); (7) Maharaj Nakorn Chiang Mai Hospital, n = 7 (1%); (8) Buri 167 n = 4 (0.6%); (9) Ubonratchathani Cancer Center, n = 2 (0.3%); (10)Ram Hospital, 168 Khon Kaen Hospital, n = 1 (0.15%) and (11) Maharat Nakhon Ratchasima Hospital, n =169 1 (0.15%). 170

A total of 711 cases of CCA patients were included in this study and separated into 2
groups namely, 154 (21.7%) cases for the screening group and 557 (78.3%) cases for the

8

173	walk-in group. The median age of patients was 61 years, where the majority were found to be
174	male 451 (63.4%). Intrahepatic CCA (iCCA) 349 (49.3%) cases were found to be the highest
175	in this study, followed by perihilar (pCCA) and distal (dCCA) CCA 282 (39.9%) and 76
176	(10.8%) cases, respectively. The screening groups had significantly higher proportions of
177	iCCA than the walk-in groups, while pCCA and dCCA were found to be significantly greater
178	in the walk-in group ( $p < 0.001$ ). Results of tumor morphology showed that the mass-forming
179	types were the major subtypes 300 (43.0%) cases in both groups. For tumor staging according
180	to the AJCC/UICC staging system, tumor stage was categorized into two groups, early stage
181	(0-II), 254 (35.7%), and late stage (III-IV), 457 (64.3%). Interestingly, tumor staging was
182	separated based on programs to detect CCA. Result showed that screening groups had
183	significantly higher CCA patients with early stage CCA 130/154 (84.4%) than walk-in
184	groups with 124/557 (22.3%) cases ( $p < 0.001$ ) (Supplementary Table 1).
185	The survival analysis was performed to calculate 5-year survival rate (5-YSR) and
186	median survival time (MST) presenting by month. The overall survival of 711 patients of this
187	study showed that MST was 19.9 months, and 5-YSR was 28.8% (Supplementary Fig 1).
188	Age, gender, and anatomical locations had no significant effect on the 5-YSR and MST in
189	this study. However, tumor morphology showed that patients with ID had significantly better
190	survival than PI, MF, and mixed type (5-YSR = 47.7 <i>vs</i> . 27.1, 24.0 and 22.9%; MST = 44.3
191	<i>vs.</i> 20.2, 14.3 and 23.7 months; HR = 1.62, 1.89 and 1.66, <i>p</i> = 0.001, < 0.001 and 0.012,
192	respectively). The comparison of the survival in early and late stage showed that patients with
193	early stage had markedly greater survival than patients with late stage $(5-YSR = 54.7)$
194	<i>vs.</i> 14.4%; MST = 78.4 <i>vs.</i> 12.3 months; HR = 3.40, $p < 0.001$ ). Interestingly,
195	patients in the walk in group had significantly greater 5-YSR and MST
196	than the walk in group (5-YSR = 53.9 vs. 21.9%; $MST = 67.2 vs. 15.6 months; HR =$
197	2.61, <i>p</i> <0.001) (Table 1 and Fig 2).

9

198
 199
 200
 201
 202
 203
 204

205

#### 206 Table 1. Univariate and multivariate analysis of the survival of CCA patients.

		5 VSD (0/)	MST (month)	Univa	riate	Multivariate	
Variable	n	5-YSR (%) (95%CI)	(95%CI)	HR (95%CI)	<i>p</i> -value	HR (95%CI)	<i>p</i> -value
Age, years							
< 61	326	26.4	19.0	1		-	
		(22.2-30.6)	(15.5-22.5)				
≥ 61	385	30.9	20.3	0.93	0.378	-	-
		(26.7-35.1)	(16.1-24.4)	(0.78-1.09)			
Gender							
Male	451	29.7	20.1	1		-	
		(25.9-33.5)	(17.1-23.1)				
Female	260	27.3	18.4	0.95	0.542	-	-
		(22.5-32.1)	(13.9-22.8)	(0.79-1.13)			
Tumor							
Location <sup>a</sup>							
dCCA	76	36.8	22.4	1		-	
		(26.5-47.1)	(18.7-26.1)				
iCCA	349	30.4	19.6	1.23	0.147	-	-
		(26.1-34.7)	(15.6-23.6)	(0.92-1.71)			
pCCA	282	25.2	18.9	1.36	0.054	-	-
		(20.8-29.6)	(15.7-22.0)	(0.99-1.86)			
Tumor							
Morphology <sup>a</sup>							
ID	128	47.7	44.3	1		1	
		(39.4-56.0)	(17.9-70.7)				
PI	221	27.1	20.2	1.62	0.001*	1.25	0.126
		(21.7-32.5)	(16.4-24.1)	(1.45-2.45)		(0.94-1.65)	
MF	300	24.0	14.3	1.89	< 0.001*	1.36	0.025*
		(19.9-28.1)	(10.8-17.8)	(1.23-2.13)		(1.04-1.78)	
Mix	48	22.9	23.7	1.66	0.012*	0.96	0.847
		(15.0-30.8)	(11.5-35.8)	(1.12-2.47)		(0.64-1.44)	
TNM stage							
Early (0-II)	254	54.7	78.4	1		1	

1	0
	~

			(48.6-60.8)	(59.7-97.2)				
	Late (III-IV)	457	14.4	12.3	3.40	< 0.001*	2.76	< 0.001*
			(11.8-16.9)	(10.5-14.1)	(2.76-4.18)		(2.15-3.55)	
	Diagnostic							
	methods	1.5.4	52.0	(7.2				
	Screening	154	53.9	67.2	1			
	Walk-In	557	21.9	15.6	2.61	< 0.001*	1 44	0.014*
	vv unit ini		(18.9-24.9)	(13.4-17.9)	(2.05-3.34)	0.001	(1.10-1.92)	0.011
207	n, Number; CI, Co	onfidenc	e interval; 5-Y	SR, 5-year survi	val rate; MST, 1	nedian surv	ival time; HR, I	hazard ratio;
208	dCCA, distal cholar	ngiocaro	cinoma; iCCA,	Intrahepatic chola	angiocarcinoma;	oCCA, perih	ilar cholangioca	rcinoma; ID,
209	intraductal; PI, peri	ductal i	nfiltrating; MF,	, mass-forming; T	NM, tumor node	metastasis f	rom 8 <sup>th</sup> AJCC/U	ЛСС staging
210	system.							
211	<sup>a</sup> The data was not	availabl	e in some case					
212	* Indicates a <i>p</i> -valu	e < 0.05	5 (statically sign	nificant)				
213								
214	Fig 2. The surv	rival of	f CCA patie	nts in screenii	ng and walk-i	n groups.		
215								
216	The sign	ificant	factors of th	e survival dete	ermined by un	ivariate inv	vestigations v	vere
217	further analyzed	l to ide	ntify any ind	lependent facto	or(s) for use as	prognosti	c prediction of	of the
218	outcome of CCA	A patie	ents which wa	as composed o	f tumor morph	nology, sta	ging and diag	gnostic
219	methods. The m	ultiva	riate analysis	showed that N	/IF morpholog	v. late CC	A stage and t	he
	11 .			1 1 4 6 4	r c	· (T		
220	waik-in group w	vere sta	atistically inc	lependent facto	ors for poor pr	ognosis (E	IR = 1.36, p =	=
221	0.025; HR = 2.7	'6, <i>p</i> <	0.001; and H	IR = 1.44, p =	0.014, respect	ively) (Tal	ble 1).	
222								
223	Subgroup a	naly	sis of scr	eening and	l walk-in g	groups	on the	
224	survival ou	tcom	es of CC	A patients	•			
225	Subgrou	p anal	ysis of each v	variable in both	n screening an	d walk-in	groups showe	ed no
	1:00 : 41		1 .	1 1	1			

227	Tumor morphology comparisons showed ID had better survival	than PI, MF, and
228	mixed type in both the screening and walk in group. Early stage of disea	ase was factor in good
229	survival of patients in both groups. There was a different outcome in tur	mor location, where
230	results showed that iCCA and pCCA had a good 5-YSR than dCCA (52	2.4 and 65.9 vs.
231	22.2%, $p < 0.05$ , respectively). In contrast, the in walk	in group, dCCA had
232	better 5-YSR than iCCA and pCCA (38.8 vs. 21.1 and 18.3%, $p < 0.001$	l, respectively) (Table
233	2 and Fig 3).	
234		

- 235
- 236

#### 237 Table 2. The comparison of the survival in CCA patients between screening and walk in

238 methods.

Variable	Screening group					Walk in group			
	n	5-YSR	HR		n	5-YSR	HR		
	(154)	(%)	(95%CI)	<i>p</i> -value	(557)	(%)	(95%CI)	<i>p</i> -value	
Age, years									
< 61	74	50.0	1		252	19.4	1		
$\geq 61$	80	57.5	0.94	0.791	305	23.9	0.89	0.224	
			(0.60-1.48)				(0.74-1.07)		
Gender									
Male	100	56.0	1		351	22.2	1		
Female	54	50.0	0.91	0.686	206	21.4	0.95	0.620	
			(0.57-1.44)				(0.79-1.15)		
Tumor									
location									
dCCA	9	22.2	1		67	38.8	1		
iCCA	103	52.4	0.39	0.021*	246	21.1	1.83	< 0.001*	
			(0.18-0.87)				(1.31-2.56)		
pCCA	41	65.9	0.28	0.005*	241	18.3	1.72	0.002*	
			(0.12-0.68)				(1.23-2.41)		
Tumor									
Morphology <sup>a</sup>									
ID	33	72.7	1		95	37.9	1		
PI	56	53.6	1.81	0.096	165	18.2	1.63	0.001*	
			(0.90-3.64)				(1.21-2.20)		
MF	59	44.1	2.25	0.020*	241	19.1	1.78	< 0.001*	
			(1.14-4.44)				(1.34-2.37)		
Mix	3	66.7	1.13	0.907	45	20.0	1.40	0.109	
			(0.15-8.77)				(0.93-2.11)		

Tumor								
staging								
Early	130	63.8	1		124	48.4	1	
Late	24	16.7	3.90	< 0.001*	433	14.3	2.73	< 0.001*
			(2.30-6.60)				(2.11-3.55)	

239 n, Number; CI, Confidence interval; 5-YSR, 5-year survival rate; HR, hazard ratio; dCCA, distal

240 cholangiocarcinoma; iCCA, Intrahepatic cholangiocarcinoma; pCCA, perihilar cholangiocarcinoma; ID,

241 intraductal; PI, periductal infiltrating; MF, mass-forming.

- 242 <sup>a</sup> The data was not available in some case
- 243 \* Indicates a *p*-value < 0.05 (statically significant)
- 244

#### Fig 3. Subgroup analysis of the survival in screening and walk in group. (A) Survival

curve of tumor location in screening and (B) walk in, (C) tumor morphology in screening and

247 (D) walk in and (E) tumor staging in screening and (F) walk in.

248

# 249 **Discussion**

250 Cholangiocarcinoma (CCA) is most common primary malignancy of bile duct epithelia 251 in the biliary tract. The northeast of Thailand has the highest incidence of CCA in the world 252 [22]. Most CCA patients are diagnosed at a late stage of the disease leading to poor survival of 253 patients due to cancer metastasis. Studies have shown that approximately 20,000 CCA patients 254 die in northeast Thailand per year leading to a significant socioeconomic burden for the 255 affected families [23]. Therefore, early diagnosis is important to enable appropriate early 256 treatment plan to be implemented, and hence, improve patient outcomes.

A previous report by Luvira V *et al* showed that only 20% of CCA patients were treated with surgical resection, while 80% of CCA patients were unresectable cases who had palliative treatments such as symptomatic treatment, chemotherapy, palliative drainage and biliary stent insertion [13]. Unfortunately, despite these palliative measures overall survival is still poor due to the advanced stage of disease leading to cancer metastasis [13, 24]. In addition, several

13

confounding complications and symptoms present at late stage, such as biliary obstruction,
obstructive jaundice and cholangitis which reduce quality of life of patients [13, 25-27]. Our
study showed that patients with late stage CCA was still currently high at approximately 64.3%
while patients with early stage CCA was 35.7%. The overall survival rate and median survival
time of CCA patients after curative surgery was 28.8% and 18.5 months which was concordant
with the range of survival outcome of CCA patients in previous reports of approximately 1025% and 17-20 months, respectively [7-12].

In 2020, Khuntikeo et al evaluated the efficiency of different methods for CCA 269 270 detection by comparing of screening programs using US by the CASCAP program (screening group) and participant walk-in with clinical symptom hospital group in 762 histologically 271 proven CCA cases. Results showed that the proportion of early stage CCA in the screening 272 273 group (0-II) was 84.5%, while it was 21.6% in walk-in group. The comparison suggested that US via active screening improves early-stage detection and was significantly higher than the 274 walk-in group, hence US is an effective tool for detecting early-stage disease of CCA [17]. The 275 276 present study was a retrospective study incorporating 11 hospitals in Thailand to compare monitoring methods comprising the screening group and a walk-in group. The 11 hospitals 277 conducted consensus procedures for US screening the suspected patients in high-risk areas, 278 while patients who came to hospital with any symptoms were classified into the walk-in group. 279 Subsequently, all patients in both groups were enroll for curative treatment by surgical 280 281 resection, and comparison of the survival outcomes of CCA between the screening group and a walk-in group was undertaken. The results showed that screening groups provided 282 significantly better survival rate and median survival than the walk-in groups (53.9 vs 21.9% 283 284 and 67.2 vs 15.6 months, respectively (Table 1). This good survival outcome was concordant with the higher proportion of early stage CCA in the screening groups (84.4%) than the walk-285 in groups (22.3%) by around 4-fold (Supplementary Table 1). Moreover, the walk-in groups 286

14

had more patients excluded from study due to advanced stage and received only palliative
surgery with mortality within 30 days. This finding may reflect advanced CCA staging and risk
of surgery in the walk-in group compared to screening group.

The screening group provides a greater number of early stage CCA patients than walk-290 in group because in the US-screening program by the CASCAP, suspected CCA cases without 291 symptoms in the high risk CCA endemic area are screened early by US, therefore, premalignant 292 lesions or early stage is usually found at the earliest possible detection time. Conversely, in the 293 walk-in group, patients present to hospital with abnormality or clinical symptoms. These 294 295 clinical symptoms are frequently correlated with CCA at an advanced stage and recorded as abnormal at the hospital admission [17, 25, 27, 28]. Therefore, results from our study show that 296 early screening is most important to enable detection of early stage of the disease which can 297 298 then provide appropriate early treatment and surveillance of patients to improve their overall survival outcome. 299

In addition, a significant finding of this study was survival outcomes concerning tumor 300 location which was obviously different. For the screening group, patients with iCCA and pCCA 301 had longer survival times than dCCA of approximately 2-fold, while in walk in groups, we 302 found that patients with dCCA had better survival than iCCA and pCCA of around 2-fold. 303 These results can be explained because US has an effective capability for detection of early 304 lesion in liver parenchyma, such as small nodules, periductal fibrosis, focal duct dilatation, 305 306 however, but some limitation of US to detect distal bile duct lesions was observed. Distal bile duct tumor can be detected by US by detecting common bile duct dilatation while most of 307 patients with common bile duct dilatation were not an early stage or had obstructive symptom 308 309 already.

According to several publications, most CCA patients in Thailand were iCCA and pCCA, and they come to hospital with symptoms which are diagnosed as late or advance stage

15

of disease, such as severe extension, lymph node and distant metastasis [29-31]. Our results 312 also showed that generally 64.3% of patients present at late stage disease. In contrast, although 313 dCCA is also present at late stage, it causes a symptom more readily. Therefore, a 5-YSR for 314 patients with dCCA (38.8%) was significantly better than iCCA (21.1%) and pCCA (18.3%) 315 as presented in walk in groups (Table 2). US screening has been reported as a tool for the early 316 detection of premalignant lesions and early stage of CCA [15-21]. The suspected CCA cases 317 without symptoms from preliminary detection were diagnosed as all types of CCA, especially 318 iCCA and pCCA for which there are no symptoms until advanced stage, resulting in early 319 320 treatment, surveillance, and improvement of overall survival. Our results showed that a 5-YSR of patients with iCCA and pCCA was markedly better than patients in walk in group. 321 Furthermore, since early monitoring was performed in screening group, almost all of the CCA 322 patients, especially those with iCCA and pCCA, had good survival than patients in the walk-323 in group, which leads to improved effective treatment, surveillance, and survival outcome in 324 CCA patients. 325

Additionally, we found that patients with early stage in screening group had 5-YSR better than walk in group (63.8 vs 48.4%, respectively) and received early management and treatment plan. Conversantly, patients having early stage in the walk-in group have some symptoms such as sepsis, malnutrition, poor physical status [17, 25, 27, 28]. These symptoms may result in poorer outcomes despite patients being in the early stage of disease. However, in the late stage of disease there were no differences in the survival outcome of both groups as several independent factors can affect on the survival of patients.

Tumor staging is well known to have an affect on the patient' survival outcome. Tumor morphology is also a potential factor to predict the survival outcome of CCA patients. Tumor morphology has been classified into four types, mass-forming (MF), periductal-infiltrating (PI), intraductal (ID), and mixed types. Basically, ID is represented as good survival in tumor

16

morphology while PI and MF are associated with aggressive features and poor survival of 337 patients [12, 21, 32-38]. This information has recently been confirmed and shows that tumor 338 morphology relates and predicts the survival outcome of all types of CCA after curative 339 surgical treatment. Results from our study also showed that tumor morphology could be a 340 predictor of survival outcomes. For instance, ID was obviously associated with longer survival 341 than PI and MF. Moreover, subgroups analysis of tumor morphology for patient's survival of 342 screening and walk-in groups also showed a similar outcome of ID having better survival than 343 PI and MF. This result could explain that screening programs had no effect on changing biology 344 345 of tumor morphology to impact on CCA patient's survival. Nevertheless, results of the screening group highlight that all types of tumor morphology had markedly better 5-YSR than 346 those in walk-in group. 347

Although this study showed several advantages of US in suspected cases who may be CCA, there is some limitation in an imbalance of numbers and variables between screening and walk in groups.

In summary, this finding revealed that ultrasound screening for CCA is an effective tool for detecting early stage CCA, and significantly improves survival outcome of CCA patients. Therefore, a comprehensive population-based programs using US for screening early stage CCA in areas of high incidence throughout Thailand and elsewhere in Southeast Asia should be undertaken.

356

## 357 Acknowledgements

All authors are truly thankful Prof. Narong Khuntikeo at Department of Surgery, Faculty of
Medicine, Khon Kaen University, Khon Kaen, Thailand, Cholangiocarcinoma Research
Institute (CARI), Khon Kaen University, Khon Kaen, Thailand and Cholangiocarcinoma
Screening and Care Program (KKU), Khon Kaen University, Khon Kaen, Thailand for helpful

17

discussions. We are also indebted to all members of CASCAP, particularly the cohort members, and researcher at CARI, Faculty of Medicine, Khon Kaen University for collecting and proofing of CCA patient data. In addition, we also thank Professor Ross H. Andrew for editing the MS via the Publication Clinic KKU, Thailand.

366

367

## **368** Author Contributions

369 **Conceptualization:** Nittaya Chamadol, Watcharin Loilome, Attapol Titapun.

**Funding acquisition:** Nittaya Chamadol, Watcharin Loilome, Attapol Titapun.

371 Sample collection and diagnosis: Nittaya Chamadol, Vallop Laopaiboon, Apiwat Jareanrat,

372 Vasin Thanasukarn, Tharatip Srisuk, Vor Luvira, Poowanai Sarkhampee, Winai

Ungpinitpong, Phummarat Khamvijite, Yutthapong Chumnanua, Nipath Nethuwakul,

Passakorn Sodarat, Samrit Thammarit, Prakasit Sa-Ngiamwibool, Attapol Titapun.

**Analysis and interpretation of data:** Jaruwan Thuanman, Chaiwat Tawarungruang, Bandit

376Thinkhamrop, Piya Prajumwongs, Attapol Titapun.

377 **Project administration:** Nittaya Chamadol, Watcharin Loilome, Attapol Titapun.

**Supervision:** Nittaya Chamadol, Watcharin Loilome, Attapol Titapun.

379 Validation: Nittaya Chamadol, Vallop Laopaiboon, Apiwat Jareanrat, Vasin Thanasukarn,

380 Tharatip Srisuk, Vor Luvira, Poowanai Sarkhampee, Winai Ungpinitpong, Phummarat

381 Khamvijite, Yutthapong Chumnanua, Nipath Nethuwakul, Passakorn Sodarat, Samrit

- 382 Thammarit, Anchalee Techasen, Jaruwan Thuanman, Chaiwat Tawarungruang, Bandit
- 383 Thinkhamrop, Prakasit Sa-Ngiamwibool, Watcharin Loilome, Piya Prajumwongs,
- 384Attapol Titapun.
- 385 Writing original draft: Nittaya Chamadol, Watcharin Loilome, Piya Prajumwongs.

Writing review and editing: Nittaya Chamadol, Anchalee Techasen, Watcharin Loilome,
Piya Prajumwongs, Attapol Titapun. All authors approved the final version of the
manuscript.

389

# **390** Conflicts of interest

391 The authors report no conflicts of interest in this work.

## 392 **References**

- 393 1. Khuhaprema T SP, Attasara P, Sriplung H, Wiangnon S,, Y S. Cancer in Thailand Vol.V,
- 394 2001–2003. Bangkok: 2010.
- 2. Haswell-Elkins MR, Satarug S, Tsuda M, Mairiang E, Esumi H, Sithithaworn P, et al. Liver
- 396 fluke infection and cholangiocarcinoma: model of endogenous nitric oxide and extragastric nitrosation
- in human carcinogenesis. Mutat Res. 1994;305(2):241-52. Epub 1994/03/01. doi: 10.1016/0027-
- 398 5107(94)90244-5. PubMed PMID: 7510035.
- 399 3. Sripa B, Kaewkes S, Sithithaworn P, Mairiang E, Laha T, Smout M, et al. Liver fluke induces
- 400 cholangiocarcinoma. PLoS Med. 2007;4(7):e201. Epub 2007/07/12. doi:
- 401 10.1371/journal.pmed.0040201. PubMed PMID: 17622191; PubMed Central PMCID:
- 402 PMCPMC1913093.
- 403 4. Yongvanit P, Pinlaor S, Bartsch H. Oxidative and nitrative DNA damage: key events in
- 404 opisthorchiasis-induced carcinogenesis. Parasitol Int. 2012;61(1):130-5. Epub 2011/06/28. doi:
- 405 10.1016/j.parint.2011.06.011. PubMed PMID: 21704729.
- 406 5. Khuntikeo N, Pugkhem A, Titapun A, Bhudhisawasdi V. Surgical management of perihilar
- 407 cholangiocarcinoma: a Khon Kaen experience. J Hepatobiliary Pancreat Sci. 2014;21(8):521-4. Epub
- 408 2014/01/28. doi: 10.1002/jhbp.74. PubMed PMID: 24464976.
- 409 6. Endo I, Gonen M, Yopp AC, Dalal KM, Zhou Q, Klimstra D, et al. Intrahepatic
- 410 cholangiocarcinoma: rising frequency, improved survival, and determinants of outcome after

19

411 resection. Ann Surg. 2008;248(1):84-96. Epub 2008/06/27. doi: 10.1097/SLA.0b013e318176c4d3.

412 PubMed PMID: 18580211.

413 7. DeOliveira ML, Cunningham SC, Cameron JL, Kamangar F, Winter JM, Lillemoe KD, et al.

414 Cholangiocarcinoma: thirty-one-year experience with 564 patients at a single institution. Ann Surg.

415 2007;245(5):755-62. Epub 2007/04/26. doi: 10.1097/01.sla.0000251366.62632.d3. PubMed PMID:

416 17457168; PubMed Central PMCID: PMCPMC1877058.

417 8. Waseem D, Tushar P. Intrahepatic, perihilar and distal cholangiocarcinoma: Management and

418 outcomes. Ann Hepatol. 2017;16(1):133-9. doi: 10.5604/16652681.1226927. PubMed PMID:

419 28051802; PubMed Central PMCID: PMCPMC5630455.

420 9. Banales JM, Marin JJG, Lamarca A, Rodrigues PM, Khan SA, Roberts LR, et al.

421 Cholangiocarcinoma 2020: the next horizon in mechanisms and management. Nat Rev Gastroenterol

422 Hepatol. 2020;17(9):557-88. Epub 2020/07/02. doi: 10.1038/s41575-020-0310-z. PubMed PMID:

423 32606456; PubMed Central PMCID: PMCPMC7447603 Sirtex, Novartis, Mylan and Delcath;

424 speaker honoraria from Merck, Pfizer, Ipsen and Incyte; and advisory honoraria from EISAI, Nutricia

and QED; she is also a member of the Knowledge Network and NETConnect Initiatives funded by

426 Ipsen. J.W.V. declares consulting or advisory roles for Agios, AstraZeneca, Delcath Systems, Keocyt,

427 Genoscience Pharma, Incyte, Ipsen, Merck, Mundipharma EDO, Novartis, PCI Biotech, Pfizer, Pieris

428 Pharmaceuticals, QED and Wren Laboratories; Speakers' Bureau for Imaging Equipment Limited,

429 Ipsen, Novartis and Nucana; and travel grants from Celgene and Nucana. J. Bridgewater declares

430 consulting or advisory roles for Merck Serono, SERVIER, Roche, Bayer, AstraZeneca, Incyte and

431 Basilea; travel support from MSD Oncology, Merck Serono, Servier and BMS. J.M.B. is scientific

432 advisor to OWL Metabolomics. M.M. is speaker for Intercept Pharma and advisor to IQVIA srl and

433 Simon & Cutcher Ltd. M.S. is a member of the Advisory Board for Bayer, Esiai/Merk and Engitix.

434 A.F. received lecture fees from Bayer, Gilead and MSD; and consultancy fees from Bayer,

435 AstraZeneca and Guerbert. J. Bruix received consultancy lecture fees from Bayer, Gilead and MSD;

436 consultancy fees from Bayer, AstraZeneca and Guerbert; research grants from Bayer, BTG;

437 educational grants from Bayer, BTG; conferences fees from Bayer, BTG and Ipsen; and fees for talks

438 from Bayer-Shering Pharma, BTG- Biocompatibles, Eisai, Terumo, Sirtex and Ipsen. P.I. receives

20

funding from AMAF Monza ONLUS and AIRCS. The remaining authors declare no competinginterests.

- 10. Le VH, O'Connor VV, Li D, Melstrom LG, Fong Y, DiFronzo AL. Outcomes of neoadjuvant
- therapy for cholangiocarcinoma: A review of existing evidence assessing treatment response and R0
- 443 resection rate. J Surg Oncol. 2021;123(1):164-71. doi: 10.1002/jso.26230. PubMed PMID: 32974932.
- 444 11. Chansitthichok S, Chamnan P, Sarkhampee P, Lertsawatvicha N, Voravisutthikul P,
- 445 Wattanarath P. Survival of Patients with Cholangiocarcinoma Receiving Surgical Treatment in an O.
- 446 viverrini Endemic Area in Thailand: A Retrospective Cohort Study. Asian Pac J Cancer Prev.
- 447 2020;21(4):903-9. Epub 2020/04/27. doi: 10.31557/APJCP.2020.21.4.903. PubMed PMID:
- 448 32334449; PubMed Central PMCID: PMCPMC7445979.
- 449 12. Kunprom W, Aphivatanasiri C, Sa-Ngiamwibool P, Sangkhamanon S, Intarawichian P,
- 450 Bamrungkit W, et al. Prognostic Significance of Growth Pattern in Predicting Outcome of
- 451 Opisthorchis viverrini-Associated Distal Cholangiocarcinoma in Thailand. Front Public Health.
- 452 2022;10:816028. Epub 2022/06/03. doi: 10.3389/fpubh.2022.816028. PubMed PMID: 35651852;
- 453 PubMed Central PMCID: PMCPMC9149579.
- 454 13. Luvira V, Nilprapha K, Bhudhisawasdi V, Pugkhem A, Chamadol N, Kamsa-ard S.
- 455 Cholangiocarcinoma Patient Outcome in Northeastern Thailand: Single-Center Prospective Study.
- 456 Asian Pac J Cancer Prev. 2016;17(1):401-6. Epub 2016/02/04. doi: 10.7314/apjcp.2016.17.1.401.
- 457 PubMed PMID: 26838246.
- Hakansson K, Ekberg O, Hakansson HO, Leander P. MR and ultrasound in screening of
  patients with suspected biliary tract disease. Acta Radiol. 2002;43(1):80-6. Epub 2002/04/26. doi:
  10.1080/028418502127347493. PubMed PMID: 11972468.
- 461 15. Chamadol N, Pairojkul C, Khuntikeo N, Laopaiboon V, Loilome W, Sithithaworn P, et al.
  462 Histological confirmation of periductal fibrosis from ultrasound diagnosis in cholangiocarcinoma
- 463 patients. J Hepatobiliary Pancreat Sci. 2014;21(5):316-22. Epub 2014/01/15. doi: 10.1002/jhbp.64.
- 464 PubMed PMID: 24420706.
- 465 16. Khuntikeo N, Loilome W, Thinkhamrop B, Chamadol N, Yongvanit P. A Comprehensive
  466 Public Health Conceptual Framework and Strategy to Effectively Combat Cholangiocarcinoma in

21

- 467 Thailand. PLoS Negl Trop Dis. 2016;10(1):e0004293. Epub 2016/01/23. doi:
- 468 10.1371/journal.pntd.0004293. PubMed PMID: 26797527; PubMed Central PMCID:
- 469 PMCPMC4721916.
- 470 17. Khuntikeo N, Koonmee S, Sa-Ngiamwibool P, Chamadol N, Laopaiboon V, Titapun A, et al.
- 471 A comparison of the proportion of early stage cholangiocarcinoma found in an ultrasound-screening
- 472 program compared to walk-in patients. HPB (Oxford). 2020;22(6):874-83. Epub 2019/10/31. doi:
- 473 10.1016/j.hpb.2019.10.010. PubMed PMID: 31662222.
- 18. Thinkhamrop K, Khuntikeo N, Chamadol N, Suwannatrai AT, Phimha S, Kelly M.
- 475 Associations between ultrasound screening findings and cholangiocarcinoma diagnosis in an at-risk
- 476 population. Sci Rep. 2022;12(1):13513. Epub 2022/08/07. doi: 10.1038/s41598-022-17794-9.
- 477 PubMed PMID: 35933509; PubMed Central PMCID: PMCPMC9357059.
- 478 19. Chamadol N, Laopaiboon V, Srinakarin J, Loilome W, Yongvanit P, Thinkhamrop B, et al.
- 479 Teleconsultation ultrasonography: a new weapon to combat cholangiocarcinoma. ESMO Open.
- 480 2017;2(3):e000231. Epub 2017/12/07. doi: 10.1136/esmoopen-2017-000231. PubMed PMID:
- 481 29209530; PubMed Central PMCID: PMCPMC5703390.
- 482 20. Khuntikeo N, Chamadol N, Yongvanit P, Loilome W, Namwat N, Sithithaworn P, et al.
- 483 Cohort profile: cholangiocarcinoma screening and care program (CASCAP). BMC Cancer.
- 484 2015;15:459. Epub 2015/06/10. doi: 10.1186/s12885-015-1475-7. PubMed PMID: 26054405;
- 485 PubMed Central PMCID: PMCPMC4459438.
- 486 21. Sungkasubun P, Siripongsakun S, Akkarachinorate K, Vidhyarkorn S, Worakitsitisatorn A,
- 487 Sricharunrat T, et al. Ultrasound screening for cholangiocarcinoma could detect premalignant lesions
- 488 and early-stage diseases with survival benefits: a population-based prospective study of 4,225 subjects
- 489 in an endemic area. BMC Cancer. 2016;16:346. Epub 2016/06/03. doi: 10.1186/s12885-016-2390-2.
- 490 PubMed PMID: 27251649; PubMed Central PMCID: PMCPMC4890519.
- 491 22. Banales JM, Cardinale V, Carpino G, Marzioni M, Andersen JB, Invernizzi P, et al. Expert
- 492 consensus document: Cholangiocarcinoma: current knowledge and future perspectives consensus
- 493 statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA). Nat Rev

Gastroenterol Hepatol. 2016;13(5):261-80. Epub 2016/04/21. doi: 10.1038/nrgastro.2016.51. PubMed

22

495	PMID:	27095655.
496	23.	Bundhamcharoen K, Odton P, Phulkerd S, Tangcharoensathien V. Burden of disease in
497	Thailan	d: changes in health gap between 1999 and 2004. BMC Public Health. 2011;11:53. Epub
498	2011/02	1/27. doi: 10.1186/1471-2458-11-53. PubMed PMID: 21266087; PubMed Central PMCID:
499	PMCPN	MC3037312.
500	24.	Park J, Kim MH, Kim KP, Park DH, Moon SH, Song TJ, et al. Natural History and
501	Progno	stic Factors of Advanced Cholangiocarcinoma without Surgery, Chemotherapy, or
502	Radioth	herapy: A Large-Scale Observational Study. Gut Liver. 2009;3(4):298-305. Epub 2010/05/01.
503	doi: 10.	5009/gnl.2009.3.4.298. PubMed PMID: 20431764; PubMed Central PMCID:
504	PMCPN	MC2852727.
505	25.	Plentz RR, Malek NP. Clinical presentation, risk factors and staging systems of
506	cholang	giocarcinoma. Best Pract Res Clin Gastroenterol. 2015;29(2):245-52. Epub 2015/05/13. doi:
507	10.1016	5/j.bpg.2015.02.001. PubMed PMID: 25966425.
508	26.	Suzuki S, Sakaguchi T, Yokoi Y, Okamoto K, Kurachi K, Tsuchiya Y, et al.
509	Clinico	pathological prognostic factors and impact of surgical treatment of mass-forming intrahepatic
510	cholang	giocarcinoma. World J Surg. 2002;26(6):687-93. Epub 2002/06/08. doi: 10.1007/s00268-001-
511	0291-1.	PubMed PMID: 12053220.

512 27. Alvaro D, Bragazzi MC, Benedetti A, Fabris L, Fava G, Invernizzi P, et al.

513 Cholangiocarcinoma in Italy: A national survey on clinical characteristics, diagnostic modalities and

treatment. Results from the "Cholangiocarcinoma" committee of the Italian Association for the Study

515 of Liver disease. Dig Liver Dis. 2011;43(1):60-5. Epub 2010/06/29. doi: 10.1016/j.dld.2010.05.002.

516 PubMed PMID: 20580332.

494

- 517 28. Ito Y, Shibutani S, Egawa T, Hayashi S, Nagashima A, Kitagawa Y. Utility of Intraductal
- 518 Ultrasonography as a Diagnostic Tool in Patients with Early Distal Cholangiocarcinoma.
- 519 Hepatogastroenterology. 2015;62(140):782-6. Epub 2016/02/24. PubMed PMID: 26902000.

23

520	29.	Sirica AE. Cholangiocarcinoma: molecular targeting strategies for chemoprevention and
521	therap	y. Hepatology. 2005;41(1):5-15. Epub 2005/02/04. doi: 10.1002/hep.20537. PubMed PMID:
522	15690	474.
523	30.	Mihalache F, Tantau M, Diaconu B, Acalovschi M. Survival and quality of life of
524	cholan	giocarcinoma patients: a prospective study over a 4 year period. J Gastrointestin Liver Dis.
525	2010;1	19(3):285-90. Epub 2010/10/06. PubMed PMID: 20922193.
526	31.	Thunyaharn N, Promthet S, Wiangnon S, Suwanrungruang K, Kamsa-ard S. Survival of
527	cholan	giocarcinoma patients in northeastern Thailand after supportive treatment. Asian Pac J Cancer
528	Prev. 2	2013;14(11):7029-32. Epub 2014/01/01. doi: 10.7314/apjcp.2012.14.11.7029. PubMed PMID:
529	24377	644.

530 32. Hwang S, Lee YJ, Song GW, Park KM, Kim KH, Ahn CS, et al. Prognostic Impact of Tumor

531 Growth Type on 7th AJCC Staging System for Intrahepatic Cholangiocarcinoma: a Single-Center

532 Experience of 659 Cases. J Gastrointest Surg. 2015;19(7):1291-304. Epub 2015/03/31. doi:

533 10.1007/s11605-015-2803-6. PubMed PMID: 25820487.

33. Aishima S, Oda Y. Pathogenesis and classification of intrahepatic cholangiocarcinoma:

535 different characters of perihilar large duct type versus peripheral small duct type. J Hepatobiliary

536 Pancreat Sci. 2015;22(2):94-100. Epub 2014/09/03. doi: 10.1002/jhbp.154. PubMed PMID:

**537** 25181580.

538 34. Dodson RM, Weiss MJ, Cosgrove D, Herman JM, Kamel I, Anders R, et al. Intrahepatic

cholangiocarcinoma: management options and emerging therapies. J Am Coll Surg. 2013;217(4):736-

540 50 e4. Epub 2013/07/31. doi: 10.1016/j.jamcollsurg.2013.05.021. PubMed PMID: 23890842.

541 35. Razumilava N, Gores GJ. Cholangiocarcinoma. Lancet. 2014;383(9935):2168-79. Epub

542 2014/03/04. doi: 10.1016/S0140-6736(13)61903-0. PubMed PMID: 24581682; PubMed Central

543 PMCID: PMCPMC4069226.

Tawarungruang C, Khuntikeo N, Chamadol N, Laopaiboon V, Thuanman J, Thinkhamrop K,
et al. Survival after surgery among patients with cholangiocarcinoma in Northeast Thailand according
to anatomical and morphological classification. BMC Cancer. 2021;21(1):497. Epub 2021/05/05. doi:

24

547 10.1186/s12885-021-08247-z. PubMed PMID: 33941120; PubMed Central PMCID:

548 PMCPMC8094526.

- 549 37. Sa-Ngiamwibool P, Aphivatanasiri C, Sangkhamanon S, Intarawichian P, Kunprom W,
- 550 Thanee M, et al. Modification of the AJCC/UICC 8th edition staging system for intrahepatic
- 551 cholangiocarcinoma: proposal for an alternative staging system from cholangiocarcinoma-prevalent
- 552 Northeast Thailand. HPB (Oxford). 2022;24(11):1944-56. Epub 2022/07/10. doi:
- 553 10.1016/j.hpb.2022.06.004. PubMed PMID: 35810105.
- 38. Aphivatanasiri C, Sa-Ngiamwibool P, Sangkhamanon S, Intarawichian P, Kunprom W,
- 555 Thanee M, et al. Modification of the eighth AJCC/UICC staging system for perihilar
- 556 cholangiocarcinoma: An alternative pathological staging system from cholangiocarcinoma-prevalent
- 557 Northeast Thailand. Front Med (Lausanne). 2022;9:893252. Epub 2022/10/18. doi:
- 558 10.3389/fmed.2022.893252. PubMed PMID: 36250068; PubMed Central PMCID:

559 PMCPMC9561347.

560

## 561 Supporting information captions

562 **S1 Table. Patient characteristics.** n–Number; CI–Confidence interval; 5-YSR–5-year 563 survival rate; dCCA–distal cholangiocarcinoma; iCCA–Intrahepatic cholangiocarcinoma; 564 pCCA–perihilar cholangiocarcinoma; ID–intraductal; PI–periductal infiltrating; MF–mass-565 forming. <sup>a</sup> The data was not available in some case. <sup>§</sup> Indicates the data were testes by Fisher's 566 exact test. <sup>\*</sup> Indicates a *p*-value < 0.05 (statically significant).

567

#### 568 S1 Fig. Overall survival of CCA patients in the study.

- 569
- 570



# Figure 1



Figure 2



Figure 3